[Moexipril and cardiovascular diseases in women: is there a reason for optimism?].
Angiotensin converting enzyme (ACE) inhibitors are first line preparations in the treatment of chronic heart failure irrespective of etiology. However there are numerous proofs that in women drugs of this group exert less pronounced favorable prognostic influence compared with men. Moexipril is an ACE inhibitor which in women demonstrated its doubtless antihypertensive efficacy with additional favorable properties. The study of efficacy of moexipril in chronic heart failure in women is able to broaden indications to the use of this drug.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000209:etiology*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology; D002908:Chronic Disease; D005260:Female; D006801:Humans; D044005:Tetrahydroisoquinolines / Q000737:chemistry / Q000627:therapeutic use*; D020257:Ventricular Remodeling / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; C058302:moexipril